サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1473829

PEG化タンパク質市場

PEGylated Proteins Market

出版日
発行
BCC Research
ページ情報
英文 74 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.69円
PEG化タンパク質市場
出版日: 2024年04月29日
発行: BCC Research
ページ情報: 英文 74 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のPEG化タンパク質の市場規模は、2023年の102億米ドルから、予測期間中は9.4%のCAGRで推移し、2028年末には159億米ドルの規模に成長すると予測されています。

地域別では、北米市場は、2023年の37億米ドルから、同期間中は8.9%のCAGRで推移し、2028年末には56億米ドルに達すると予測されています。欧州市場は、2023年の32億米ドルから、CAGR 9.5%で推移し、2028年末には51億米ドルに達すると予測されています。

当レポートでは、世界のPEG化タンパク質の市場を調査し、市場概要、法規制環境、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

  • 市場の展望
  • 調査範囲
  • 市場サマリー

第2章 市場概要

  • PEG化タンパク質の利点
  • PEG化治療薬の限界

第3章 市場力学

  • 市場力学：スナップショット
  • 市場促進要因
  • 血液および腫瘍におけるタンパク質医薬品
  • バイオベターズのデザイン
  • 市場抑制要因
  • 免疫原性と副作用
  • 処方の課題
  • 市場機会
  • 部位特異的PEG化
  • 新しい適応症と製剤技術

第4章 新興技術と開発

  • 非共有結合性PEG化
  • ナノ粒子のPEG化
  • 抗体薬物複合体（ADC）

第5章 市場分析：各種区分別

  • 分類の内訳
  • 世界のPEG化タンパク質市場：タンパク質タイプ別
  • 顆粒球コロニー刺激因子（G-CSF）
  • PEG化モノクローナル抗体
  • ペグ化インターフェロン
  • PEG化組み換え因子
  • その他
  • 世界のPEG化タンパク質市場：PEG化タイプ別
  • 直鎖PEG化タンパク質
  • 分岐PEG化タンパク質
  • 世界のPEG化タンパク質市場：PEG化用途別
  • 自己免疫疾患
  • 血液
  • 癌
  • その他
  • 世界のPEG化タンパク質市場：地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第6章 競合情報

  • 最近の動向
  • 臨床試験活動

第7章 PEG化タンパク質市場における持続可能性：ESGの観点

  • PEG化タンパク質産業における持続可能性
  • ESGデータの理解
  • 環境パフォーマンス
  • 社会的パフォーマンス
  • ガバナンスパフォーマンス
  • BCCによる総論

第8章 付録

  • 調査手法
  • 出典
  • 略語
  • 企業プロファイル
  • AMGEN INC.
  • F. HOFFMANN-LA ROCHE LTD.
  • MERCK KGAA
  • PFIZER INC.
  • SANDOZ GROUP AG
図表

List of Tables

  • Summary Table : Global Market for PEGylated Proteins, by Region, Through 2028
  • Table 1 : PEGylated Drugs in Clinical Trials for Cancer
  • Table 2 : Discontinued PEGylated Drugs in Clinical Trials
  • Table 3 : Side Effects Observed with Approved Products
  • Table 4 : Global Market for PEGylated Proteins, by Protein Type, Through 2028
  • Table 5 : Marketed PEGylated G-CSF Drugs
  • Table 6 : Global Market for G-CSF, by Region, Through 2028
  • Table 7 : Global Market for PEGylated mAbs, by Region, Through 2028
  • Table 8 : Global Market for PEGylated Interferons, by Region, Through 2028
  • Table 9 : Global Market for PEGylated Recombinant Factors, by Region, Through 2028
  • Table 10 : Global Market for Other Protein Types, by Region, Through 2028
  • Table 11 : Global Market for PEGylated Proteins, by PEGylation Type, Through 2028
  • Table 12 : Global Market for Linear PEGylated Proteins, by Region, Through 2028
  • Table 13 : Global Market for Branched PEGylated Proteins, by Region, Through 2028
  • Table 14 : Global Market for PEGylated Proteins, by Application, Through 2028
  • Table 15 : Global Market for PEGylated Proteins for Autoimmune Diseases, by Region, Through 2028
  • Table 16 : Global Market for PEGylated Proteins for Hematology, by Region, Through 2028
  • Table 17 : Global Market for PEGylated Proteins for Cancer, by Region, Through 2028
  • Table 18 : Global Market for PEGylated Proteins for Other Applications, by Region, Through 2028
  • Table 19 : Global Market for PEGylated Proteins, by Region, Through 2028
  • Table 20 : North American Market for PEGylated Proteins, by Country, Through 2028
  • Table 21 : North American Market for PEGylated Proteins, by Protein Type, Through 2028
  • Table 22 : North American Market for PEGylated Proteins, by PEGylation Type, Through 2028
  • Table 23 : North American Market for PEGylated Proteins, by Application, Through 2028
  • Table 24 : European Market for PEGylated Proteins, by Country, Through 2028
  • Table 25 : European Market for PEGylated Proteins, by Protein Type, Through 2028
  • Table 26 : European Market for PEGylated Proteins, by PEGylation Type, Through 2028
  • Table 27 : European Market for PEGylated Proteins, by Application, Through 2028
  • Table 28 : Asia-Pacific Market for PEGylated Proteins, by Country, Through 2028
  • Table 29 : Asia-Pacific Market for PEGylated Proteins, by Protein Type, Through 2028
  • Table 30 : Asia-Pacific Market for PEGylated Proteins, by PEGylation Type, Through 2028
  • Table 31 : Asia-Pacific Market for PEGylated Proteins, by Application, Through 2028
  • Table 32 : RoW Market for PEGylated Proteins, by Protein Type, Through 2028
  • Table 33 : RoW Market for PEGylated Proteins, by PEGylation Type, Through 2028
  • Table 34 : RoW Market for PEGylated Proteins, by Application, Through 2028
  • Table 35 : Recent Developments in PEGylated Proteins Market, 2022 and 2023
  • Table 36 : Competitor Clinical Trial Activities in PEGylated Protein Therapeutics, by Phase, 2023
  • Table 37 : ESG Risk Rankings for Major PEGylated Protein Drug Companies*
  • Table 38 : ESG: Environmental Overview
  • Table 39 : ESG: Social Overview
  • Table 40 : ESG: Governance Overview
  • Table 41 : Report Sources
  • Table 42 : Abbreviations Used in this Report
  • Table 43 : Amgen Inc.: Company Snapshot
  • Table 44 : Amgen Inc.: Financial Performance, FY 2022 and 2023
  • Table 45 : Amgen Inc.: Product Portfolio
  • Table 46 : Amgen Inc.: News/Key Developments, 2023
  • Table 47 : F. Hoffmann-La Roche Ltd.: Company Snapshot
  • Table 48 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
  • Table 49 : F. Hoffmann-La Roche Ltd.: Product Portfolio
  • Table 50 : Merck KGaA: Company Snapshot
  • Table 51 : Merck KGaA: Financial Performance, FY 2022 and 2023
  • Table 52 : Merck KGaA: Product Portfolio
  • Table 53 : Merck KGaA: News/Key Developments, 2022 and 2023
  • Table 54 : Pfizer Inc.: Company Snapshot
  • Table 55 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
  • Table 56 : Pfizer Inc.: Product Portfolio
  • Table 57 : Pfizer Inc.: News/Key Developments, 2023
  • Table 58 : Sandoz Group AG: Company Snapshot
  • Table 59 : Sandoz Group AG: Financial Performance, FY 2022 and 2023
  • Table 60 : Sandoz Group AG: Product Portfolio
  • Table 61 : Sandoz Group AG: News/Key Developments, 2023

List of Figures

  • Summary Figure : Global Market for PEGylated Proteins, by Region, 2020-2028
  • Figure 1 : Advantages of Protein PEGylation
  • Figure 2 : Timeline of PEGylated Protein Therapeutics
  • Figure 3 : Disadvantages of PEGylated Protein Therapeutics
  • Figure 4 : Market Dynamics of Global PEGylated Proteins
  • Figure 5 : Emerging Technologies in the PEGylated Proteins Market
  • Figure 6 : Global Market Shares of PEGylated Proteins, by Protein Type, 2022
  • Figure 7 : Global Market for G-CSF, by Region, 2020-2028
  • Figure 8 : Global Market for PEGylated mAbs, by Region, 2020-2028
  • Figure 9 : Global Market for PEGylated Interferons, by Region, 2020-2028
  • Figure 10 : Global Market for PEGylated Recombinant Factors, by Region, 2020-2028
  • Figure 11 : Global Market for Other Protein Types, by Region, 2020-2028
  • Figure 12 : Global Market Shares of PEGylated Proteins, by PEGylation Type, 2022
  • Figure 13 : Global Market for Linear PEGylated Proteins, 2020-2028
  • Figure 14 : Global Market for Linear PEGylated Proteins, by Region, 2020-2028
  • Figure 15 : Global Market for Branched PEGylated Proteins, 2020-2028
  • Figure 16 : Global Market for Branched PEGylated Proteins, by Region, 2020-2028
  • Figure 17 : Global Market Shares of PEGylated Proteins, by Application, 2022
  • Figure 18 : Global Market for PEGylated Proteins for Autoimmune Diseases, 2020-2028
  • Figure 19 : Global Market for PEGylated Proteins for Autoimmune Diseases, by Region, 2020-2028
  • Figure 20 : Global Market for PEGylated Proteins for Hematology, 2020-2028
  • Figure 21 : Global Market for PEGylated Proteins for Hematology, by Region, 2020-2028
  • Figure 22 : Global Market for PEGylated Proteins for Cancer, 2020-2028
  • Figure 23 : Global Market for PEGylated Proteins for Cancer, by Region, 2020-2028
  • Figure 24 : Global Market for PEGylated Proteins for Other Applications, 2020-2028
  • Figure 25 : Global Market for PEGylated Proteins for Other Applications, by Region, 2020-2028
  • Figure 26 : Global Market Shares of PEGylated Proteins, by Region, 2022
  • Figure 27 : Global Market for PEGylated Proteins, by Region, 2020-2028
  • Figure 28 : North American Market Shares of PEGylated Proteins, by Country, 2022
  • Figure 29 : European Market Shares of PEGylated Proteins, by Country, 2022
  • Figure 30 : Asia-Pacific Market Shares of PEGylated Proteins, by Country, 2022
  • Figure 31 : Snapshot of ESG Pillars
  • Figure 32 : Advantages of ESG for Companies
  • Figure 33 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023
  • Figure 34 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
  • Figure 35 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
  • Figure 36 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
  • Figure 37 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
  • Figure 38 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
  • Figure 39 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
  • Figure 40 : Sandoz Group AG: Revenue Share, by Business Unit, FY 2023
  • Figure 41 : Sandoz Group AG: Revenue Share, by Country/Region, FY 2023
目次
Product Code: BIO253A

The global market for PEGylated proteins is expected to grow from $10.2 billion in 2023 and projected to reach $15.9 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.4% during the forecast period of 2023 to 2028. 

North American market for PEGylated proteins is expected to grow from $3.7 billion in 2023 and projected to reach $5.6 billion by the end of 2028, at a CAGR of 8.9% during the forecast period of 2023 to 2028. 

The European market for PEGylated proteins is expected to grow from $3.2 billion in 2023 and projected to reach $5.1 billion by the end of 2028, at a CAGR of 9.5% during the forecast period of 2023 to 2028.

Report Scope

This report highlights the current and future market potential of PEGylated proteins and provides a detailed analysis of the drivers, restraints, and opportunities in this market. The report also surveys the competitive environment for PEGylated proteins, including coverage of the pipeline activities adopted by players in this market, and it includes market projections for 2028. Also included are company profiles of key players featuring detailed information about each company's business segments, financials, product portfolios and recent developments. The report does not cover PEGylated vaccines.

In this report, the global market for PEGylated proteins market is segmented into four regions: North America, Europe, Asia-Pacific and Rest of the World. For market estimates, data is provided for 2020 and 2021 (which serve as the historic years), for 2022 (the base year), and forecast for 2028.

Report Includes

  • 41 data tables and 22 additional tables
  • Analysis of the PEGylated proteins market
  • Analyses of global market trends, with revenue data for 2021-2022, estimates for 2023, forecasts for 2024, and projected CAGRs through 2028
  • Estimates of the current market size and revenue growth prospects, along with a market share analysis by product and services, protein type, application, and region
  • Facts and figures pertaining to the market drivers, opportunities and restraints, and the impact of macroeconomic variables
  • An analysis of recent patent grants and published patents
  • A look at emerging technologies and regulatory issues
  • Overview of sustainability trends and ESG developments, including consumer attitudes, companies' ESG score rankings and their ESG practices
  • Insight into the competitive landscape, including companies' market shares, business segments, financials and product portfolios, as well as recent M&A activity and venture funding outlook
  • Profiles of the major market players

Table of Contents

Chapter 1 Executive Summary

  • Market Outlook
  • Scope of Report
  • Market Summary

Chapter 2 Market Overview

  • Introduction
  • Advantages of Protein PEGylation
  • Limitations of PEGylated Therapeutics

Chapter 3 Market Dynamics

  • Market Dynamics Snapshot
  • Market Drivers
  • Protein Drugs in Hematology and Oncology
  • Design of Biobetters
  • Market Restraints
  • Immunogenicity and Side Effects
  • Formulation Challenges
  • Market Opportunities
  • Site-Specific PEGylation
  • New Indications and Formulation Techniques

Chapter 4 Emerging Technologies and Developments

  • Introduction
  • Non-Covalent PEGylation
  • PEGylation of Nanoparticles
  • Antibody-Drug Conjugates (ADCs)

Chapter 5 Market Segmentation Analysis

  • Segmentation Breakdown
  • Global PEGylated Proteins Market, by Protein Type
  • Granulocyte-Colony Stimulating Factors (G-CSF)
  • PEGylated Monoclonal Antibodies
  • PEGylated Interferons
  • PEGylated Recombinant Factors
  • Other Protein Types
  • Global PEGylated Proteins Market, by PEGylation Type
  • Linear PEGylated Proteins
  • Branched PEGylated Proteins
  • Global PEGylated Proteins Market, by PEGylation Application
  • Autoimmune Diseases
  • Hematology
  • Cancer
  • Other Applications
  • Geographic Breakdown
  • Global Market for PEGylated Proteins, by Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 6 Competitive Intelligence

  • Recent Developments in the PEGylated Proteins Market
  • Clinical Trial Activities

Chapter 7 Sustainability in the PEGylated Proteins Market: ESG Perspective

  • Introduction
  • Sustainability in the PEGylated Proteins Industry
  • Understanding the ESG Data
  • Environmental Performance
  • Social Performance
  • Governance Performance
  • Concluding Remarks from BCC

Chapter 8 Appendix

  • Methodology
  • Sources
  • Abbreviations
  • Company Profiles
  • AMGEN INC.
  • F. HOFFMANN-LA ROCHE LTD.
  • MERCK KGAA
  • PFIZER INC.
  • SANDOZ GROUP AG